Adding abiraterone to hormone therapy at start of treatment for prostate cancer improves survival by 37%, published in New England Journal of Medicine. The trial could change standard of care for men with prostate cancer, making abiraterone a first-line treatment alongside hormone therapy.

See the source article by following the link below:
Adding abiraterone to hormone therapy at start of treatment for prostate cancer improves survival by 37%, published in New England Journal of Medicine. The trial could change standard of care for men with prostate cancer, making abiraterone a first-line treatment alongside hormone therapy.